Zosano Pharma has entered into a pharma deal with Novo Nordisk to develop a new transdermal presentation of semaglutide for $155 million.
Semaglutide is an investigational proprietary human GLP-1 (Glucagon-Like Peptide-1) analogue, to be administered once weekly using Zosano's microneedle patch system for the treatment of type 2 diabetes.
Zosano and Novo Nordisk will engage in collaborative efforts to carry out preclinical experiments to verify delivery of semaglutide using Zosano's microneedle patch system.
Zosano will grant Novo Nordisk a worldwide, exclusive license to develop and commercialize Novo Nordisk's proprietary GLP-1 analogues using Zosano's microneedle patch system.
Novo Nordisk will, pending successful outcomes of preclinical and clinical testing, be responsible for commercialization of all products under the agreement.
Potential payments to Zosano under the agreement include an upfront payment and additional payments upon achieving certain preclinical, clinical, regulatory and sales milestones.
Such payments could total more than $60 million for the first product and $55 million for each additional product.
Zosano is also eligible to receive royalties on sales of products and will receive development support, as well as reimbursement of all development and manufacturing costs.
For further deal information visit Current Agreements (subscription required)
Report: Diabetes Partnering
Report: Partnering Deals and Alliances with Novo Nordisk
View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity
View: Current Partnering’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity